Chromadex (NASDAQ:CDXC) has been given a $8.00 price target by equities researchers at HC Wainwright in a report released on Sunday, March 11th. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 57.17% from the stock’s previous close.
Several other analysts have also issued reports on CDXC. Zacks Investment Research upgraded Chromadex from a “hold” rating to a “buy” rating and set a $7.50 price objective for the company in a report on Tuesday, November 28th. ValuEngine lowered Chromadex from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, BidaskClub lowered Chromadex from a “strong-buy” rating to a “buy” rating in a report on Friday, December 22nd. Two analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $7.50.
Shares of Chromadex (CDXC) opened at $5.09 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.36 and a current ratio of 7.08. Chromadex has a 1-year low of $2.26 and a 1-year high of $7.24.
Chromadex (NASDAQ:CDXC) last announced its quarterly earnings data on Thursday, March 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.17). Chromadex had a negative return on equity of 52.15% and a negative net margin of 48.68%. The business had revenue of $7.53 million during the quarter, compared to analyst estimates of $7.50 million. analysts anticipate that Chromadex will post -0.1 earnings per share for the current fiscal year.
In other Chromadex news, CEO Frank L. Jaksch, Jr. sold 28,379 shares of the stock in a transaction on Thursday, January 11th. The shares were sold at an average price of $6.52, for a total transaction of $185,031.08. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Frank L. Jaksch, Jr. sold 58,400 shares of the stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $6.19, for a total transaction of $361,496.00. The disclosure for this sale can be found here. Corporate insiders own 11.59% of the company’s stock.
Institutional investors have recently bought and sold shares of the business. Oppenheimer & Co. Inc. acquired a new position in Chromadex during the fourth quarter worth $250,000. Cetera Advisor Networks LLC acquired a new position in Chromadex during the fourth quarter worth $147,000. Monashee Investment Management LLC acquired a new position in Chromadex during the fourth quarter worth $140,000. Granite Investment Partners LLC increased its position in Chromadex by 5.7% during the third quarter. Granite Investment Partners LLC now owns 250,276 shares of the company’s stock worth $1,076,000 after buying an additional 13,599 shares during the last quarter. Finally, Deutsche Bank AG increased its position in Chromadex by 31,769.4% during the fourth quarter. Deutsche Bank AG now owns 22,946 shares of the company’s stock worth $134,000 after buying an additional 22,874 shares during the last quarter. 10.30% of the stock is currently owned by hedge funds and other institutional investors.
Chromadex Company Profile
Chromadex Corporation and its subsidiaries ChromaDex, Inc, ChromaDex Analytics, Inc and Spherix Consulting, Inc provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets.
Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.